The management of a patient in cardiac failure should lead the physician to
ask if the patient might benefit from treatment with an angiotensin conver
ting inhibitor. Meta-analyses give a positive reply but often lack detail.
Analysis of large scale the-individual case, This analysis starts with vali
dation of the methodology (correct randomisation, respect of double blind p
rotocol, identity of groups) and synthesis of results expressed, if possibl
e, in absolute values. In a second stage, the criteria of inclusion, exclus
ion, and the comorbidity of enrolled patients, should be compared with thos
e of the patient under consideration. In addition, the amplitude of the the
rapeutic benefit and the importance of undesired effects must be taken into
account in the therapeutic decision. This approach allows a reasoned presc
ription based on documented facts.